No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [11C]FLB 457 in the human cortex

Synapse

Volumn 64, Issue 12, 2010, Pages 879-885

  Frankle, W Gordon ^a   Mason, N Scott ^a   Rabiner, Eugenii A ^b,c   Ridler, Khanum ^b   May, Maureen A ^a   Asmonga, Deanna ^a   Chen, Chi Min ^a   Kendro, Steve ^a   Cooper, Thomas B ^d   Mathis, Chester A ^a   Narendran, Rajesh ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Columbia University ^*  (United States)

Author keywords

11C FLB 457; AMPT; DA; human cortex; PET

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ISOREMOXIPRIDE C 11; METIROSINE; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; CATECHOLAMINE DEPLETION; CINGULATE GYRUS; CLINICAL EVALUATION; DOPAMINE RELEASE; DRUG BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; NEUROPSYCHIATRY; NORMAL HUMAN; OCCIPITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; TEMPORAL LOBE;

ADULT; ALPHA-METHYLTYROSINE; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CEREBRAL CORTEX; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 77958190262     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20806     Document Type: Article

References (55)

1. Abi-Dargham A., Laruelle M., Seibyl J., Rattner Z., Baldwin RM., Zoghbi SS., Zea-Ponce Y., Bremner JD., Hyde TM., Charney DS., Hoffer PB., Innis RB..1994.SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: Kinetic and equilibrium paradigms.J Nucl Med35:228-238.
2. 11C]NNC 112 in humans: Validation and reproducibility.J Cereb Blood Flow Metab20:225-243.
3. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles LS., Weiss R., Cooper TB., Mann JJ., Van Heertum RL., Gorman JM., Laruelle M..2000b.From the cover: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.Proc Natl Acad Sci USA97:8104-8109.
4. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang DR., Keilp J., Kochan L., Van Heertum R., Gorman JM., Laruelle M..2002.Prefrontal dopamine D1 receptors and working memory in schizophrenia.J Neurosci22:3708-3719.
5. Benjamini Y., Hochberg Y..1995.Controlling the false discovery rate: A practical and powerful approach to multiple testing.J R Stat Soc Ser B289-300.
6. Breier A., Su TP., Saunders R., Carson RE., Kolachana BS., de Bartolomeis A., Weinberger DR., Weisenfeld N., Malhotra AK., Eckelman WC., Pickar D..1997.Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method.Proc Natl Acad Sci USA94:2569-2574.
7. Brodie HK., Murphy DL., Goodwin FK., Bunney W.Jr.1971.Catecholamines and mania: The effect of α-methyl-para-tyrosine on manic behavior and catecholamine metabolism.Clin Pharmacol Ther12:218-224.
8. Carson RE., Breier A., de Bartolomeis A., Saunders RC., Su TP., Schmall B., Der MG., Pickar D., Eckelman WC..1997.Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion.J Cereb Blood Flow Metab17:437-447.
9. Cropley VL., Innis RB., Nathan PJ., Brown AK., Sangare JL., Lerner A., Ryu YH., Sprague KE., Pike VW., Fujita M..2008.Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.Synapse62:399-408.
10. Endres CJ., Kolachana BS., Saunders RC., Su T., Weinberger D., Breier A., Eckelman WC., Carson RE..1997.Kinetic modeling of [C-11]raclopride: Combined PET-microdialysis studies.J Cereb Blood Flow Metab17:932-942.
11. Engelman K., Jequier E., Udenfriend S., Sjoerdsman A..1968.Metabolism of α-methyltyrosine in man: Relationship to its potency as an inhibitor of catecholamine biosynthesis.J Clin Invest47:568-576.
12. Fadda F., Gessa GL., Marcou M., Mosca E., Rossetti Z..1984.Evidence for dopamine autoreceptors in mesocortical dopamine neurons.Brain Res293:67-72.
13. Fujita M., Verhoeff NP., Varrone A., Zoghbi SS., Baldwin RM., Jatlow PA., Anderson GM., Seibyl JP., Innis RB..2000.Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans.Eur J Pharmacol387:179-188.
14. Gandelman MS., Baldwin RM., Zoghbi SS., Zea-Ponce Y., Innis RB..1994.Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: Β-CIT, IBF and iomazenil.J Pharm Sci83:1014-1019.
15. Gunn RN., Sargent PA., Bench CJ., Rabiner EA., Osman S., Pike VW., Hume SP., Grasby PM., Lammertsma AA..1998.Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY- 100635 for PET.Neuroimage8:426-440.
16. Halldin C., Farde L., Hogberg T., Mohell N., Hall H., Suhara T., Karlsson P., Nakashima Y., Swahn CG..1995.Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors.J Nucl Med36:1275-1281.
17. Hill A..1910.The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves.J Physiol (Lond)40:4-7.
18. Innis RB., Cunningham VJ., Delforge J., Fujita M., Gjedde A., Gunn RN., Holden J., Houle S., Huang SC., Ichise M., Iida H., Ito H., Kimura Y., Koeppe RA., Knudsen GM., Knuuti J., Lammertsma AA., Laruelle M., Logan J., Maguire RP., Mintun MA., Morris ED., Parsey R., Price JC., Slifstein M., Sossi V., Suhara T., Votaw JR., Wong DF., Carson RE..2007.Consensus nomenclature for in vivo imaging of reversibly binding radioligands.J Cereb Blood Flow Metab27:1533-1539.
19. Kegeles LS., Zea-Ponce Y., Abi-Dargham A., Rodenhiser J., Wang T., Weiss R., Van Heertum RL., Mann JJ., Laruelle M..1999.Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.Synapse31:302-308.
20. Kegeles L., Abi-Dargham A., Frankle W., Gil R., Cooper T., Slifstein M., Hwang D-R., Huang Y., Haber S., Laruelle M..2010.Increased synaptic dopamine in associative regions of the striatum in schizophrenia.Arch Gen Psychiatry67:231-239.
21. Khan ZU., Gutierrez A., Martin R., Penafiel A., Rivera A., De La Calle A..1998.Differential regional and cellular distribution of dopamine D2-like receptors: An immunocytochemical study of subtype-specific antibodies in rat and human brain.J Comp Neurol402:353-371.
22. Lammertsma AA., Hume SP..1996.Simplified reference tissue model for PET receptor studies.Neuroimage4(3, Pt 1):153-158.
23. Lang AE., Marsden CD..1982.Alpha methylparatyrosine and tetrabenazine in movement disorders.Clin Neuropharmacol5:375-387.
24. Laruelle M..2000.Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review.J Cereb Blood Flow Metab20:423-451.
25. Laruelle M., Abi-Dargham A., van Dyck CH., Rosenblatt W., Zea-Ponce Y., Zoghbi SS., Baldwin RM., Charney DS., Hoffer PB., Kung HF., Innis RB..1995.SPECT imaging of striatal dopamine release after amphetamine challenge.J Nucl Med36:1182-1190.
26. Laruelle M., Abi-Dargham A., van Dyck CH., Gil R., De Souza CD., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi SS., Baldwin RM., Seibyl JP., Krystal JH., Charney DS., Innis RB..1996.Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects.Proc Natl Acad Sci USA93:9235-9240.
27. Laruelle M., D'Souza CD., Baldwin RM., Abi-Dargham A., Kanes SJ., Fingado CL., Seibyl JP., Zoghbi SS., Bowers MB., Jatlow P., Charney DS., Innis RB..1997a.Imaging D2 receptor occupancy by endogenous dopamine in humans.Neuropsychopharmacology17:162-174.
28. Laruelle M., Iyer RN., Al-Tikriti MS., Zea-Ponce Y., Malison R., Zoghbi SS., Baldwin RM., Kung HF., Charney DS., Hoffer PB., Innis RB., Bradberry CW..1997b.Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.Synapse25:1-14.
29. Malison RT., Mechanic KY., Hea K..1999.Reduced amphetamine-stimulated dopamine release in cocaine addicts as measured by [123I]IBZM SPECT.J Nucl Med40:110P.
30. Martinez D., Gil R., Slifstein M., Hwang DR., Huang Y., Perez A., Kegeles L., Talbot P., Evans S., Krystal J., Laruelle M., Abi-Dargham A..2005.Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum.Biol Psychiatry58:779-786.
31. Martinez D., Narendran R., Foltin RW., Slifstein M., Hwang DR., Broft A., Huang Y., Cooper TB., Fischman MW., Kleber HD., Laruelle M..2007.Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine.Am J Psychiatry164:622-629.
32. Martinez D., Greene K., Broft A., Kumar D., Liu F., Narendran R., Slifstein M., Van Heertum R., Kleber HD..2009.Lower level of endogenous dopamine in patients with cocaine dependence: Findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion.Am J Psychiatry166:1170-1177.
33. Miller HL., Delgado PL., Salomon RM., Heninger GR., Charney DS..1996.Effects of α-methyl-para-tyrosine (AMPT) in drug-free depressed patients.Neuropsychopharmacology14:151-157.
34. Mintun MA., Raichle ME., Kilbourn MR., Wooten GF., Welch MJ..1984.A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography.Ann Neurol15:217-227.
35. Mukherjee J., Yang ZY., Das MK., Brown T..1995.Fluorinated benzamide neuroleptics. III. Development of S-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D2 receptor tracer.Nucl Med Biol22:283-296.
36. Mukherjee J., Shi B., Christian BT., Chattopadhyay S., Narayanan TK..2004.11C-fallypride: Radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain.Bioorg Med Chem12:95-102.
37. 11C]fallypride.Synapse63:447-461.
38. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain.J Cereb Blood Flow Metab19:1164-1173.
39. Olsson H., Halldin C., Farde L..2004.Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET.Neuroimage22:794-803.
40. Riccardi P., Baldwin R., Salomon R., Anderson S., Ansari MS., Li R., Dawant B., Bauernfeind A., Schmidt D., Kessler R..2008.Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.Biol Psychiatry63:241-244.
41. Slifstein M., Hwang DR., Huang Y., Guo N., Sudo Y., Narendran R., Talbot P., Laruelle M..2004a.In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.Psychopharmacology (Berl)175:274-286.
42. Slifstein M., Narendran R., Hwang DR., Sudo Y., Talbot PS., Huang Y., Laruelle M..2004b.Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies.Synapse54:46-63.
43. Smith SM., Jenkinson M., Woolrich MW., Beckmann CF., Behrens TE., Johansen-Berg H., Bannister PR., De Luca M., Drobnjak I., Flitney DE., Niazy RK., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady JM., Matthews PM..2004.Advances in functional and structural MR image analysis and implementation as FSL.Neuroimage23 (Suppl 1):S208-S219.
44. 11C]FLB 457 binding in extrastriatal regions.Nucl Med Commun22:1215-1221.
45. Suhara T., Sudo Y., Okauchi T., Maeda J., Kawabe K., Suzuki K., Okubo Y., Nakashima Y., Ito H., Tanada S., Halldin C., Farde L..1999.Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET.Int J Neuropsychopharmcol2:73-82.
46. Verhoeff NP., Kapur S., Hussey D., Lee M., Christensen B., Psych C., Papatheodorou G., Zipursky RB..2001.A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects.Neuropsychopharmacology25:213-223.
47. Verhoeff NP., Hussey D., Lee M., Tauscher J., Papatheodorou G., Wilson AA., Houle S., Kapur S..2002.Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans.Mol Psychiatry7:233, 322-238.
48. 11C]FLB 457-A test-retest analysis.Eur J Nucl Med27:1666-1673.
49. 11C]raclopride continuous infusion PET scans.Synapse33:268-273.
50. Volkow ND., Wang GJ., Fowler JS., Logan J., Gatley SJ., Hitzemann R., Chen AD., Dewey SL., Pappas N..1997.Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects.Nature386:830-833.
51. Watson C..2000.New, faster, image-based scatter correction for 3D PET.IEEE Trans Nucl Sci47:1587-1594.
52. Wu S., Ogden RT., Mann JJ., Parsey RV..2007.Optimal metabolite curve fitting for kinetic modeling of 11C-WAY-100635.J Nucl Med48:926-931.
53. Youngren KD., Inglis FM., Pivirotto PJ., Jedema HP., Bradberry CW., Goldman-Rakic PS., Roth RH., Moghaddam B..1999.Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus.Neuropsychopharmacology20:403-412.
54. Yung KK., Bolam JP., Smith AD., Hersch SM., Ciliax BJ., Levey AI..1995.Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy.Neuroscience65:709-730.
55. Zhang Y., Brady M., Smith S..2001.Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.IEEE Trans Med Imag20:45-57.